Comparison of the efficiency of phytoremediation of soil contaminated with different types of oil products

The object of research. Effectiveness of phytoremediation of soil contaminated with different types of oil products. Investigated problem. When studying the problem of soil contamination by oil products and when looking for ways to restore soils disturbed by the chemical effects of hydrocarbon fuels, the type of oil product is not always taken into account. And a generalization is used for this type of pollution, as pollution by oil products, which does not take into account the difference in the component composition of hydrocarbon motor fuels and their different impact on the ecological state of the soil. The main scientific results. The research results established the dependence of the effectiveness of phytoremediation of soil contaminated with oil products on the type of oil product. The obtained data made it possible to draw a conclusion about the nature of the dependence of qualitative and quantitative indicators of the level of soil phytoremediation by a certain type of plant, depending on the hydrocarbon composition of the oil product. The area of practical use of research results. The results of the research will be used in practice when choosing the type of plants to restore the quality of soil contaminated with a certain type of oil product. Innovative technological product. The results of the study created the basis for the development of a scientific and methodological approach to the resolved issues of restoring the quality of soil contaminated by various types of petroleum products. What can be used by specialists in the future in the development of new technologies for the restoration of soils contaminated with petroleum products. Scope of the innovative technological product. Research results and the proposed scientific and methodological approach concern the sphere of environmental protection and transport enterprises

CO2 Hydrogenation to Methanol over Ce and Zr Containing UiO-66 and Cu/UiO-66

Direct hydrogenation of CO2 to methanol is an interesting method to recycle CO2 emitted e.g., during combustion of fossil fuels. However, it is a challenging process because both the selectivity to methanol and its production are low. The metal-organic frameworks are relatively new class of materials with a potential to be used as catalysts or catalysts supports, also in the reaction of MeOH production. Among many interesting structures, the UiO-66 draws significant attention owing to its chemical and thermal stability, developed surface area, and the possibility of tuning its properties e.g., by exchanging the zirconium in the nodes to other metal cations. In this work we discuss—for the first time—the performance of Cu supported on UiO-66(Ce/Zr) in CO2 hydrogenation to MeOH. We show the impact of the composition of UiO-66-based catalysts, and the character of Cu-Zr and Cu-Ce interactions on MeOH production and MeOH selectivity during test carried out for 25 h at T = 200 °C and p = 1.8 MPa. Significant increase of selectivity to MeOH was noticed after exchanging half of Zr4+ cations with Ce4+; however, no change in MeOH production occurred. It was found that the Cu-Ce coexistence in the UiO-66-based catalytic system reduced the selectivity to MeOH when compared to Cu/UiO-66(Zr), which was ascribed to lower concentration of Cu0 active sites in Cu/UiO-66(Ce/Zr), and this was caused by oxygen spill-over between Cu0 and Ce4+, and thus, the oxidation of the former. The impact of reaction conditions on the structure stability of tested catalyst was also determined.This work was financed by a statutory activity subsidy from the Polish Ministry of Science and Higher Education for the Faculty of Chemistry of Wrocław University of Technology and the project 0402/0100/17

Peculiarities of the crystal structure evolution of Bifeo3-batio3 ceramics across structural phase transitions

Evolution of the crystal structure of ceramics BiFeO3-BaTiO3 across the morphotropic phase boundary was analyzed using the results of macroscopic measuring techniques such as X-ray diffraction, differential scanning calorimetry, and differential thermal analysis, as well as the data obtained by local scale methods of scanning probe microscopy. The obtained results allowed to specify the concentration and temperature regions of the single phase and phase coexistent regions as well as to clarify a modification of the structural parameters across the rhombohedral-cubic phase boundary. The structural data show unexpected strengthening of structural distortion specific for the rhombohedral phase, which occurs upon dopant concentration and temperature-driven phase transitions to the cubic phase. The obtained results point to the non-monotonous character of the phase evolution, which is specific for metastable phases. The compounds with metastable structural state are characterized by enhanced sensitivity to external stimuli, which significantly expands the perspectives of their particular use. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.Instituto Nacional de Ciência e Tecnologia para Excitotoxicidade e Neuroproteção, INCT-EN: UID/04564/2020, UIDB/50011/2020, UIDP/50011/2020Russian Science Foundation, RSF: 18-19-00307Funding: This work was supported by the RSF (project #18-19-00307). Investigations performed at the Center for Physics of the University of Coimbra were supported by Fundação para a Ciência e a Tecnologia (project UID/04564/2020). M.V.S. acknowledges Russian academic excellence project “5-100” for Sechenov University. Part of work done at the University of Aveiro was developed within the scope of the project CICECO-Aveiro Institute of Materials, refs. UIDB/50011/2020 & UIDP/50011/2020, financed by national funds through the FCT/MEC

The Tissue Microlocalisation and Cellular Expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 Is Correlated to Clinical Outcome in NSCLC

BACKGROUND: We have previously investigated the microlocalisation of M1 and M2 macrophages in NSCLC. This study investigated the non-macrophage (NM) expression of proteins associated with M1 and M2 macrophages in NSCLC. METHODS: Using immunohistochemistry, CD68(+) macrophages and proteins associated with either a cytotoxic M1 phenotype (HLA-DR, iNOS, and MRP 8/14), or a non-cytotoxic M2 phenotype (CD163 and VEGF) were identified. NM expression of the markers was analysed in the islets and stroma of surgically resected tumours from 20 patients with extended survival (ES) (median 92.7 months) and 20 patients with poor survival (PS) (median 7.7 months). RESULTS: The NM expression of NM-HLA-DR (p<0.001), NM-iNOS (p = 0.02) and NM-MRP 8/14 (p = 0.02) was increased in ES compared to PS patients in the tumour islets. The tumour islet expression of NM-VEGF, was decreased in ES compared to PS patients (p<0.001). There was more NM-CD163 expression (p = 0.04) but less NM-iNOS (p = 0.002) and MRP 8/14 (p = 0.01) expression in the stroma of ES patients compared with PS patients. The 5-year survival for patients with above and below median NM expression of the markers in the islets was 74.9% versus 4.7% (NM-HLA-DR p<0.001), 65.0% versus 14.6% (NM-iNOS p = 0.003), and 54.3% versus 22.2% (NM-MRP 8/14 p = 0.04), as opposed to 34.1% versus 44.4% (NM-CD163 p = 0.41) and 19.4% versus 59.0% (NM-VEGF p = 0.001). CONCLUSIONS: Cell proteins associated with M1 and M2 macrophages are also expressed by other cell types in the tumour islets and stroma of patients with NSCLC. Their tissue and cellular microlocalisation is associated with important differences in clinical outcome

Differential Expression of CD163 on Monocyte Subsets in Healthy and HIV-1 Infected Individuals

CD163, a haptoglobin-hemoglobin (Hp-Hb) scavenger receptor, expressed by monocytes and macrophages, is important in resolution of inflammation. Age-related non-AIDS co-morbidities in HIV-infected individuals, particularly dementia and cardiovascular disease, result in part from effects of HIV-1 infection on monocyte and macrophage biology. CD163 co-expression on CD14+CD16++ monocytes has been proposed as a useful biomarker for HIV-1 disease progression and the presence of HIV associated dementia. Here we investigated CD163 expression on monocyte subsets ex vivo, on cultured macrophages, and soluble in plasma, in the setting of HIV-1 infection. Whole blood immunophenotyping revealed CD163 expression on CD14++CD16- monocytes but not on CD14+CD16++ monocytes (P = 0.004), supported by CD163 mRNA levels. Incubation with M-CSF induced CD163 protein expression on CD14+CD16++ monocytes to the same extent as CD14++CD16− monocytes. CD163 expression on CD14++CD16+ monocytes from HIV-infected subjects was significantly higher than from uninfected individuals, with a trend towards increased expression on CD14++CD16− monocytes (P = 0.019 and 0.069 respectively), which is accounted for by HIV-1 therapy including protease inhibitors. Shedding of CD163 was shown to predominantly occur from the CD14++CD16− subset after Ficoll isolation and LPS stimulation. Soluble CD163 concentration in plasma from HIV-1 infected donors was similar to HIV-1 uninfected donors. Monocyte CD163 expression in HIV-1 infected patients showed a complicated relationship with classical measures of disease progression. Our findings clarify technical issues regarding CD163 expression on monocyte subsets and further elucidates its role in HIV-associated inflammation by demonstrating that CD163 is readily lost from CD14++CD16− monocytes and induced in pro-inflammatory CD14+CD16++ monocytes by M-CSF. Our data show that all monocyte subsets are potentially capable of differentiating into CD163-expressing anti-inflammatory macrophages given appropriate stimuli. Levels of CD163 expression on monocytes may be a potential biomarker reflecting efforts by the immune system to resolve immune activation and inflammation in HIV-infected individuals

Differential Expression of CD163 on Monocyte Subsets in Healthy and HIV-1 Infected Individuals

CD163, a haptoglobin-hemoglobin (Hp-Hb) scavenger receptor, expressed by monocytes and macrophages, is important in resolution of inflammation. Age-related non-AIDS co-morbidities in HIV-infected individuals, particularly dementia and cardiovascular disease, result in part from effects of HIV-1 infection on monocyte and macrophage biology. CD163 co-expression on CD14+CD16++ monocytes has been proposed as a useful biomarker for HIV-1 disease progression and the presence of HIV associated dementia. Here we investigated CD163 expression on monocyte subsets ex vivo, on cultured macrophages, and soluble in plasma, in the setting of HIV-1 infection. Whole blood immunophenotyping revealed CD163 expression on CD14++CD16- monocytes but not on CD14+CD16++ monocytes (P = 0.004), supported by CD163 mRNA levels. Incubation with M-CSF induced CD163 protein expression on CD14+CD16++ monocytes to the same extent as CD14++CD16− monocytes. CD163 expression on CD14++CD16+ monocytes from HIV-infected subjects was significantly higher than from uninfected individuals, with a trend towards increased expression on CD14++CD16− monocytes (P = 0.019 and 0.069 respectively), which is accounted for by HIV-1 therapy including protease inhibitors. Shedding of CD163 was shown to predominantly occur from the CD14++CD16− subset after Ficoll isolation and LPS stimulation. Soluble CD163 concentration in plasma from HIV-1 infected donors was similar to HIV-1 uninfected donors. Monocyte CD163 expression in HIV-1 infected patients showed a complicated relationship with classical measures of disease progression. Our findings clarify technical issues regarding CD163 expression on monocyte subsets and further elucidates its role in HIV-associated inflammation by demonstrating that CD163 is readily lost from CD14++CD16− monocytes and induced in pro-inflammatory CD14+CD16++ monocytes by M-CSF. Our data show that all monocyte subsets are potentially capable of differentiating into CD163-expressing anti-inflammatory macrophages given appropriate stimuli. Levels of CD163 expression on monocytes may be a potential biomarker reflecting efforts by the immune system to resolve immune activation and inflammation in HIV-infected individuals

Identification and manipulation of tumor associated macrophages in human cancers

Evading immune destruction and tumor promoting inflammation are important hallmarks in the development of cancer. Macrophages are present in most human tumors and are often associated with bad prognosis. Tumor associated macrophages come in many functional flavors ranging from what is known as classically activated macrophages (M1) associated with acute inflammation and T-cell immunity to immune suppressive macrophages (M2) associated with the promotion of tumor growth. The role of these functionally different myeloid cells is extensively studied in mice tumor models but dissimilarities in markers and receptors make the direct translation to human cancer difficult. This review focuses on recent reports discriminating the type of infiltrating macrophages in human tumors and the environmental cues present that steer their differentiation. Finally, immunotherapeutic approaches to interfere in this process are discussed